---
title: "EPS HEALTH TECH plans to acquire a 16.23% stake in China Gene"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274636736.md"
description: "On February 3, 2026, EPS HEALTH TECH signed a memorandum of understanding with Hongshida Medical Co., Ltd. to acquire a 16.23% stake in China Gene Engineering Co., Ltd., with a transaction amount of approximately HKD 40 million to 45 million. China Gene primarily engages in the research, development, manufacturing, and sales of biopharmaceuticals. After the acquisition, it will become an associate investment of the group. The board believes that this move will create long-term value for the group in the healthcare industry"
datetime: "2026-02-03T10:22:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274636736.md)
  - [en](https://longbridge.com/en/news/274636736.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274636736.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274636736.md) | [English](https://longbridge.com/en/news/274636736.md)


# EPS HEALTH TECH plans to acquire a 16.23% stake in China Gene

According to the Zhitong Finance APP, EPS HEALTH TECH (03860) announced that on February 3, 2026, the company (as the buyer) entered into a memorandum of understanding with Hongshida Medical Limited (as the seller) regarding the proposed acquisition of a 16.23% equity stake in China Gene Engineering Co., Ltd. (China Gene). China Gene is a company registered in Hong Kong, which beneficially owns approximately 67.68% of Shanghai Huaxin Biological High-Tech Co., Ltd. (Huaxin). Huaxin is a company registered in the People's Republic of China, and together with China Gene and its subsidiaries, is referred to as the "China Gene Group." The consideration amounts to approximately HKD 40 million to HKD 45 million.

The China Gene Group primarily engages in the internal research and development, manufacturing, and sales of biopharmaceutical products in China, complementing the group's existing core businesses of trading healthcare products, leasing medical devices, and providing professional contract research organization (CRO) services. Upon completion of the proposed acquisition, the group's investment in China Gene will be recognized as an investment in an associate in the group's consolidated financial statements.

The board of directors believes that the proposed acquisition represents an excellent opportunity for the group to expand its involvement in the operations of the China Gene Group; it is also a strategic investment that creates potential long-term value for the group and facilitates the group's business development in the promising healthcare industry

### 相關股票

- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [GF CSI All Share Health Care ETF (159938.CN)](https://longbridge.com/zh-HK/quote/159938.CN.md)
- [EPS HEALTH TECH (03860.HK)](https://longbridge.com/zh-HK/quote/03860.HK.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-HK/quote/159929.CN.md)
- [BGI Genomics (300676.CN)](https://longbridge.com/zh-HK/quote/300676.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-HK/quote/589720.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)

## 相關資訊與研究

- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-HK/news/281501537.md)
- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-HK/news/281035304.md)
- [Barclays Sticks to Its Buy Rating for UCB SA (0NZT)](https://longbridge.com/zh-HK/news/280966907.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-HK/news/281644038.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/zh-HK/news/281343251.md)